This Tiny Float Nasdaq Biotech (CMND) Has 5 Must-Know Potential Catalysts Right Now

Let's throw the breaks on for a second. This Tiny Float Nasdaq Biotech (CMND) Has 5 Must-Know Potential Catalysts Right Now January 25th Dear Reader, Let's throw the breaks on for a second. Did you catch what happened last week? Tuesday's profile blasted approximately 59% in two days. Wednesday's profile surged approximately 27% intraday. Friday's profile jumped approximately 14% intraday. Count that up and what do you get? That's approximately 100% in combined runs. Not shabby, but here comes something to get your eyes glued on. This cutting-edge company is developing remarkable treatments for mental health, alcohol use disorder, binge eating, and depression. And with a [portfolio of 23 patent filings,]( this company's innovative treatments offer the potential for revolutionary changes in multiple health-related fields. Add in a spicy low float under 2Mn shares, a recent Nasdaq uplisting, and tons of game-changing news to kick off 2023, and we could be talking about the most important biotech company flying under Wall Street's radar right now. Right now, drop everything and get this Nasdaq profile on your radar: *Clearmind Medicine Inc. (CMND)* Clearmind is a psych-e-delic pharmaceutical biotech company focused on the discovery and development of novel psych-e-delic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psych-e-delic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. And based on these 5 potential catalysts, CMND needs immediate attention. Check them out: No. 1 - A Tiny Float Could Provide Access To Extreme Volatility No. 2 - Positive Results Signal Pre-Clinical Study Trending In Right Direction No. 3 - New Batch Of CMND-100 Manufactured For First In-Human Clinical Trial No. 4 - Company's Drug Candidate, MEAI, Could Treat Obesity And Metabolic Syndrome No. 5 - Nasdaq Uplisting Creates Incredible Exposure Opp. But more on those in a second... The Problem: Alcohol Use Disorder. Clearmind’s flagship treatments are focused on Alcohol Use Disorder (AUD), which is incredibly common. It varies from mild to excessive, and describes a person’s inability to restrict their alcohol consumption, despite negative social, occupational, or health consequences. - Alcohol consumption is the 3rd leading preventable cause of death in the US. - The yearly cost of excessive alcohol use in the US reached $249Bn in 2010. - Alcohol consumption contributes to 3 million deaths each year globally... In addition to disabilities and poor health of millions of people. - World Health Organization ----- The Solution: MEAI (5-Methoxy-2-aminoindane) 5-Methoxy-2-aminoindane (MEAI) is a psychoactive molecule, exerting a euphoric alcohol-like experience and a reduced desire to consume alcoholic beverages. It shows a good safety profile in pre-clinical studies, with potential to change the lives of millions who struggle to drink in moderation. Breaking the Cycle We believe that MEAI breaks the vicious binge-drinking cycle at the decision point to drink more alcohol, by potentially innervating neural pathways such as 5-HT1A that lead to “sensible behaviour.” Non-Addictive Anecdotal reports and pre-clinical in-vivo results indicate the self-limiting property of MEAI—unlike traditional treatments. Expansive Potential The literature shows that 5-HT1A receptors are associated with controlling craving behavior across the board. This indicates that MEAI may have a wide range of applications beyond binge drinking. ----- Successful Pre-clinical Results In MEAI Treatment For Alcohol Consumption Pre-clinical trial demonstrated a high safety profile in addition to a significant suppressive effect on alcohol consumption. - Clearmind conducted preclinical trials, training groups of mice to consume alcohol for five weeks - The groups were then given a daily dose of MEAI, with intermittent access to alcohol and water - After two weeks, researchers found a significant reduction in alcohol consumption in mice receiving MEAI - The untreated control group showed no significant reduction in alcohol consumption - No SAEs or treatment-related histological changes were observed amongst all MEAI treatment groups compared to control naive and vehicle animals in all the examined organs Low Competitive Intensity Only 3 other psych-e-delic companies are working on alcohol abuse problems: The Company's Competitive Advantage Most companies in the psych-e-delics field target depression and anxiety. - Clearmind focuses on binge behaviors and addictions: A huge untapped market Most companies develop classic psych-e-delics for which intellectual property is hard to file and approve. - Clearmind is the sole developer of MEAI and has a robust portfolio of protected intellectual property Most psych-e-delic treatments are designed to be adjuncts to psychotherapy. - MEAI is designed to be self administered, due to its high safety potential, and not in conjunction to psychotherapy ----- Proprietary Treatment Candidates Grab Sources And More From The [CMND Company Presentation.]( ----- And as I mentioned above, CMND has several potential catalysts that could provide a breakout spark near term. Here they are: No. 1 CMND Potential Catalyst - A Tiny Float Could Provide Access To Extreme Volatility According to the [Yahoo Finance website]( CMND has a tiny float. The website reports this profile to have approximately 1.17Mn shares in its float. Why is that important? It's important on one crucial level. Volatility. With so few shares available for trading, other potential catalysts (like big news) could spark a vertical move in the short-term. ----- No. 2 CMND Potential Catalyst - Positive Results Signal Pre-Clinical Study Trending In Right Direction Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Co-caine Addiction Treatment The results of pre-clinical in-vivo research studies suggested that Clearmind's drug candidate MEAI may be effective in the treatment of substance addiction without interrupting the natural reward process Tel Aviv, Israel / Vancouver, Canada, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psych-e-delic-derived therapeutics to solve major under-treated health problems, today announced additional positive pre-clinical results in its ongoing series of research studies conducted to illuminate the tremendous potential of MEAI and its effect on substance-use-disorder (SUD). The latest in-vivo studies examined the effect of MEAI on the natural reward process as it pertains to co-caine addiction. The pre-clinical studies were led by Professor Gal Yadid from the Gonda Multidisciplinary Brain Research Center at Bar Ilan University in Israel. As previously announced (see press release August 24, 2022), Clearmind's proprietary MEAI at a dose of 5mg/kg, demonstrated unique ability to decrease co-caine craving and potentially become the first dedicated co-caine addiction treatment. The latest research studies were designed to evaluate the effects of MEAI on natural reward, as reward-based positive reinforcement is a shared evolutionary survival strategy across species. However, in drug addiction, reward seeking becomes maladaptive and endangers survival. The purpose of this in-vivo study, was to conclude whether MEAI uses the same mechanisms that underlie the seeking of both drug and natural rewards (such as sucrose). The results demonstrated that natural reward was maintained in the MEAI-treated rats, thus showing that the effect of MEAI on drug-seeking is not related to the general reward system. “We are thrilled to continuously exhibit positive results of our proprietary drug candidate MEAI. The results of these latest in-vivo studies reinforce previous findings and demonstrate that MEAI may be an effective treatment addiction without negatively affecting natural reward," said Dr. Adi Zuloff-Shani, Clearmind's Chief Executive Officer. “Co-caine is extremely addictive and there is currently no dedicated treatment. I believe Clearmind is leading the way in this field." Professor Gal Yadid stated “Very interesting results were revealed in this set of in-vivo studies. The empirical data show that MEAI is a potential treatment for co-caine addiction, in particular, and SUD, in general. This observation is based on our experience and previous data from testing various treatments for SUD. Further studies are needed to better characterize the responding population.” [Read the full article here.]( ----- No. 3 CMND Potential Catalyst - New Batch Of CMND-100 Manufactured For First In-Human Clinical Trial Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial Tel Aviv, Israel / Vancouver, Canada, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND) (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psych-e-delic-derived therapeutics to solve major undertreated health problems, announced that it has successfully manufactured batches of its drug candidate, MEAI-based molecule CMND-100, for use in its first in-human clinical trial. The trial will evaluate the psych-e-delic-derived drug candidate for the treatment of Alcohol Use Disorder (AUD). “Having our drug candidate ready to be tested is a major milestone toward our first in-human clinical trial,” said Dr. Adi Zuloff-Shani, Clearmind’s Chief Executive Officer. “Our pre-clinical positive results indicated the potential of our unique treatment for AUD. We continue to execute the final steps necessary in order to commence our clinical program.” The drug candidate was produced under GMP (Good Manufacturing Process) conditions to comply with FDA requirements. [Read the full article here.]( ----- No. 4 CMND Potential Catalyst - Company's Drug Candidate, MEAI, Could Treat Obesity And Metabolic Syndrome Israel-Based Clearmind Medicine Shows Efficacy of Psych-e-delic- Derived Obesity Treatment in Pre-Clinical Trial In a series of pre-clinical trials, Clearmind’s drug candidate MEAI significantly reduced body weight, improved fatty liver disease, and normalized insulin sensitivity Tel Aviv, Israel / Vancouver, Canada, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psych-e-delic-derived therapeutics to solve major undertreated health problems, today announced positive pre-clinical results demonstrating efficacy of its drug candidate MEAI for treating obesity and metabolic syndrome. The study, conducted at the Hebrew University of Jerusalem, as part of a collaboration established with the university’s technology transfer company, Yissum, included multi-parameter metabolic assessments such as body weight, fat mass, glucose tolerance, insulin sensitivity, liver enzymes and fat accumulation as well as food consumption patterns. It included three groups of rodents: one was fed a standard diet, another a high-fat diet, and the third a high-fat diet group along with treatment with MEAI. The animals treated with MEAI showed increased energy expenditure, better fat utilization and weight loss of 20%, while reducing their overall fat mass and preserving their lean body mass. No effect on motivation and well-being was observed. Additionally, MEAI treatment yielded normalization of insulin levels, improved glucose tolerance as well as reduced fat and triglycerides accumulation in the liver. These results were significantly better than those obtained in the high fat, untreated group. Furthermore, a significant reduction in sucrose preference was observed following administration of MEAI for two days at the effective dose, supporting the notion that it can dampen the hedonic value of rewarding stimuli. Thus, MEAI may be beneficial for the treatment of compulsive reward-seeking behavior or excessive consumption of sweet foods. "We’re very excited about these results, which suggest that MEAI may be effective in treating obesity, one of the world's most pressing problems," said Dr. Adi Zuloff-Shani, Clearmind's Chief Executive Officer. “These additional positive results in our treatment of addictions, once again indicate MEAI’s potential to become a viable treatment for a variety of disorders.” Dr. Adi Zuloff-Shani also noted that the global market for obesity drugs was valued by third-party sources in 2021 at $1.9Bn. The study was led by Prof. Joseph Tam, D.M.D., Ph.D., head of the Obesity and Metabolism Laboratory and Associate Professor of Pharmacology at the Hebrew University’s Institute for Drug Research and Dr. Saja Baraghithy, Ph.D. “While there is some evidence suggesting that psychedelic drugs, such as L-S-D and psi-lo-cybin, may be effective in treating obesity and other eating disorders, no solid experimental proof really exists, until now. We show for the first time that MEAI’s obesity effect works by altering various metabolic processes in the body, such as energy expenditure, fat storage and glucose utilization to promote weight loss,” said Prof. Tam. “These findings suggest that MEAI may be beneficial for reducing the risk of obesity-related complications, such as type 2 diabetes and fatty liver diseases.” ... [Read the full article here.]( ----- No. 5 CMND Potential Catalyst - Nasdaq Uplisting Creates Incredible Exposure Opp. Clearmind Medicine Announces Closing of $7.5Mn Public Offering and Uplisting to the Nasdaq Capital Market VANCOUVER, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq and CSE: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), ..., today announced the closing of its underwritten public offering of 1,153,847 common shares at a price to the public of $6.50 per share (CAD$8.65), for aggregate gross proceeds of $7.5Mn, prior to deducting underwriting discounts and offering expenses. The closing occurs following a 1-for-30 reverse st-ock split, which was effective at 5:30 p.m. on September 30, 2022. ... [Read the full article here.]( Aegis Capital Corp. Acted as Sole Bookrunner on a $7.5Mn Underwritten Public Offering & Uplisting for Clearmind Medicine Inc. (NASDAQ: CMND) NEW YORK, NY / ACCESSWIRE / November 17, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on a $7.5Mn Underwritten Public Offering & Uplisting for Clearmind Medicine Inc. (NASDAQ:CMND). [Read the full article here.]( ----- CMND Recap - The Top 5 Potential Breakout Catalysts For This Nasdaq Past Champ No. 1 - A Tiny Float Could Provide Access To Extreme Volatility No. 2 - Positive Results Signal Pre-Clinical Study Trending In Right Direction No. 3 - New Batch Of CMND-100 Manufactured For First In-Human Clinical Trial No. 4 - Company's Drug Candidate, MEAI, Could Treat Obesity And Metabolic Syndrome No. 5 - Nasdaq Uplisting Creates Incredible Exposure Opp. ----- Coverage is officially reinitiated on CMND. When time permits, do this: Get CMND on your radar now. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Ownership of FI has now moved to a single individual. Disclosure: I am not a lic-ensed fina-ncial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Fierce full disclosure is to be read and fully understood before using Fierce's website, or joining Fierce's email or text list. By viewing Fierce's website and/or reading Fierce's email or text newsletter you are agreeing to -> [( An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates stockwirenews . com (“SWN”), and owns and operates stockstreetwire . com ("SSW"). From time to time, SWN, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SWN Media LLC and TD Media, LLC, FierceInvestor (FI) has been hired for a period beginning on 1/24/23 and ending on 1/25/23 to publicly disseminate information about (CMND) via Website, Email and SMS. SWN Media LLC was paid five thousand USD via bank wire transfer. We own zero shares of (CMND). To date we have now been compensated a total of fifteen thousand USD via bank wire transfer to disseminate information about (CMND). Pursuant to an agreement between SWN Media LLC and Legends Media LLC, FierceInvestor (FI) has been hired for a period beginning on 11/23/22 and ending on 11/25/22 to publicly disseminate information about (CMND) via Website, Email and SMS. SWN Media LLC was paid ten thousand USD via bank wire transfer. We own zero shares of (CMND). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and Atlanta Capital Partners LLC, TD Media LLC has been hired for a period beginning on 12/12/2022 and ending on 02/03/2023 to publicly disseminate information about (CMND:US) (CMND:CA) via digital communications. We have been paid two hundred twenty thousand dollars USD via bank wire transfer. We own zero shares of (CMND:US) (CMND:CA). [( Fierce | 539 W Commerce St, Dallas, TX 75208 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.net